00791nam0-2200289 --450 991056339990332120220510114656.0978379138588420220510d2019----kmuy0itay5050----baengDEa c 001yy50 buildings you should knowIsabel KuhlMunich [etc.]Prestel2019157 p.ill.25 cmFifty buildings you should knowArchitetturaStoriaEdifici storici720.9Kühl,Isabel1222683ITUNINARICAUNIMARCBK9910563399903321ARCH B 3889211/2022FARBCFARBC50 buildings you should know2836051UNINA05361nam 22015613a 450 991034668430332120250203235429.09783039210619303921061010.3390/books978-3-03921-061-9(CKB)4920000000094826(oapen)https://directory.doabooks.org/handle/20.500.12854/54029(ScCtBLL)9b5b364c-2670-4301-9845-c4b9a0365ea7(OCoLC)1117844310(oapen)doab54029(EXLCZ)99492000000009482620250203i20192019 uu engurmn|---annantxtrdacontentcrdamediacrrdacarriermTOR in Human DiseasesOlivier DormondMDPI - Multidisciplinary Digital Publishing Institute2019Basel, Switzerland :MDPI,2019.1 electronic resource (480 p.)9783039210602 3039210602 The mechanistic target of rapamycin (mTOR) is a major signaling intermediary that coordinates favorable environmental conditions with cell growth. Indeed, as part of two functionally distinct protein complexes, named mTORC1 and mTORC2, mTOR regulates a variety of cellular processes, including protein, lipid, and nucleotide synthesis, as well as autophagy. Over the last two decades, major molecular advances have been made in mTOR signaling and have revealed the complexity of the events implicated in mTOR function and regulation. In parallel, the role of mTOR in diverse pathological conditions has also been identified, including in cancer, hamartoma, neurological, and metabolic diseases. Through a series of articles, this book focuses on the role played by mTOR in cellular processes, metabolism in particular, and highlights a panel of human diseases for which mTOR inhibition provides or might provide benefits. It also addresses future studies needed to further characterize the role of mTOR in selected disorders, which will help design novel therapeutic approaches. It is therefore intended for everyone who has an interest in mTOR biology and its application in human pathologies.Medicinebicsscprimary cilianeurodegenerationnutrient sensorPI3Ktranscriptomicsphosphorylationmetabolic reprogrammingautophagyAlzheimer's diseaserapalogsliverangiogenesismTOR complexMBSCsadvanced biliary tract cancersMedulloblastomaepithelial to mesenchymal transitionAMPKp70S6Klipid metabolismthyroid cancersodium iodide symporter (NIS)/SLC5A5male fertilityanesthesiailluminamTOR inhibitormiRNAHutchinson-Gilford progeria syndrome (HGPS)eIFsEmery-Dreifuss muscular dystrophy (EDMD)glucoseAKToral cavity squamous cell carcinoma (OSCC)glucose and lipid metabolismcellular signalingagingtumor microenvironmentrapamycinleukemiachloral hydraterapaloguesschizophreniaT-cell acute lymphoblastic leukemiasenescencelamin A/Cneurotoxicityneurodevelopmentinhibitormethamphetaminepulmonary fibrosismTORmTOR inhibitorscombination therapyproteolysisfluid shear stresstumour cachexiabiomarkerssynapsegluconeogenesismTOR signal pathwaySertoli cellsimmunosenescencemiRNomeprotein aggregationsenolyticsmetabolismNGSmTORC2mTORC1metabolic diseasesIonTorrentapoptosisdopamine receptornocodazolemicroenvironmenteverolimusacute myeloid leukemiaimmunotherapyspermatogenesisbone remodelingsignallingtargeted therapyageingtherapyNVP-BEZ235fructosephysical activitylaminopathiesMC3T3-E1 cellscell signalingmicroRNAcancerlipolysismelatoninParkinson's diseaseMedicineDormond Olivier1331033ScCtBLLScCtBLLBOOK9910346684303321MTOR in Human Diseases3040048UNINA